Peanut Patch

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT)

Study phase: III

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

  • Male or female from 1-3 years of age at Visit
  • Physician-diagnosed peanut allergy or high suspicion of peanut allergy as assessed by the physician:
    • child presenting signs, symptoms and a medical and/or a family history putting him/her at high risk of having a peanut allergy
    • and/or history of presence of peanut-specific IgE and/or positive SPT
  • Subject currently following a strict peanut-free diet
  • Peanut-specific IgE level (ImmunoCAP system) > 0.7 kU/L
  • Positive peanut SPT with a largest wheal diameter ≥ 6 mm

Primary disease category: Allergy & Immunology

Sponsor: DBV Technologies

Protocol number: Epitope, V712-304

Projected enrollment dates: April 2018 to May 2020

Official study title: A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.